Wockhardt U.K. expands Byetta manufacturing capacity

By Elaine Rigoli

Tampa, Fla., June 16 - Wockhardt Ltd. said Friday that it plans to build a new facility in September to expand its capacity for the manufacture of Byetta (Exenatide) cartridges.

"Our factory has been operating seven days a week to supply Byetta. We unilaterally and proactively decided to invest in new cartridge capacity," Wockhardt U.K. managing director Sirjiwan Singh said in a news release.

The expansion project, currently under way, will raise the cartridge manufacturing capacity by four times from the current capacity, the release said.

Wockhardt, currently the only supplier of Byetta cartridges, said this new facility is in response to some reports that Eli Lilly, the company marketing Byetta, may be advising physicians to limit the number of patients they start on the new diabetes drug because of a shortage of Byetta.

Wockhardt U.K. is a subsidiary of the India-based pharmaceutical and biotechnology company Wockhardt Ltd.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.